GlassScriptPhysician profile
Christina Ynares
NPI 1407838931
$863.90
in general payments reported to CMS, 2019-2025
10 companies · $58.18 in 2025
The $58.18 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $100 · 2021: $140 · 2022: $141 · 2024: $39.73 · 2025: $58.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $76.49 · Education: $21.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $76.49 |
| Education | $21.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $272.11 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $175.67 | 2019-2025 | Lokelma |
| Opko Pharmaceuticals, LLC | $128.73 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $74.94 | 2019-2020 | |
| Akebia Therapeutics INC | $72.10 | 2019-2025 | Vafseo |
| Veloxis Pharmaceuticals, INC. | $68.65 | 2019 | |
| Baxter Healthcare | $37.38 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.58 | 2022 | |
| Daiichi Sankyo INC. | $15.08 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Ynares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.